[Sn-117m]-DOTA-Annexin V is under clinical development by Serene and currently in Phase II for Atherosclerosis. According to GlobalData, Phase II drugs for Atherosclerosis have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how [Sn-117m]-DOTA-Annexin V’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
[Sn-117m]-DOTA-Annexin V overview
Sn-117m-DOTA-Annexin V is under development for the treatment of vulnerable plaque (atherosclerosis). The drug candidate comprises of radioisotope Tin-117m conjugated to annexin V. It is administered through intravenous route and acts by targeting phosophatidylserine.
It was under development for the treatment of carotid artery stenosis, abdominal aortic aneurysm and coronary artery stenosis.
Serene overview
Serene, formerly Serene Oncology, is a drug discovery company that develops and commercializes radiolabeled diagnostic and therapeutic products for rheumatologic, cardiovascular, arthritis and oncologic conditions. The company’s pipeline product candidate, tin-117m is a radioisotope that produces conversion electrons. Its product tin-117 provides the technology platform and the active component of several drugs and devices for the treatment of cancers like hepatocellular carcinoma, and cholangiocarcinoma, rheumatologic, atherosclerotic and other diseases. Serene’ pipeline comprises pharmaceutical candidates targeted at the treatment of bone metastases, abdominal aortic aneurysms, carotid artery stenosis and coronary artery stenosis among others. Serene is headquartered in Houston, Texas, the US.
For a complete picture of [Sn-117m]-DOTA-Annexin V’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
